Stock listing
COAG Stock Price, News, Filings & Events — Hemab Therapeutics Holdings, Inc.
Selected listing: COAG · BOATS · USD · US
This page tracks Hemab Therapeutics Holdings, Inc.'s COAG:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following COAG:BOATS. COAG:BOATS is the stock-level entry point for investors researching Hemab Therapeutics Holdings, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Hemab Therapeutics Holdings, Inc. is a public company traded under the ticker COAG in the American market. The company has a market capitalization of approximately $2.3 billion. Hemab focuses on developing innovative therapies for patients with rare diseases.

- Ticker
- COAG:BOATS
- Asset type
- Stock
- Market cap
- $1.84B
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
Hemab Therapeutics Holdings, Inc. COAG:BOATS stock context
This page tracks Hemab Therapeutics Holdings, Inc.'s COAG:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following COAG:BOATS. COAG:BOATS is the stock-level entry point for investors researching Hemab Therapeutics Holdings, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Hemab Therapeutics Holdings, Inc. is a public company traded under the ticker COAG in the American market. The company has a market capitalization of approximately $2.3 billion. Hemab focuses on developing innovative therapies for patients with rare diseases.
Latest news from Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the IST...
July 14, 2026
Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding ...
July 12, 2026
Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
May 27, 2026
Hemab Therapeutics Reports First Quarter 2026 Financial Results
May 21, 2026
Research Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. investor report
Review AI stock analysis and investor report context for COAG:BOATS.
Hemab Therapeutics Holdings, Inc. company profile
View the public company page for Hemab Therapeutics Holdings, Inc. on 6ix.
Hemab Therapeutics Holdings, Inc. news
Read company news and market updates connected to Hemab Therapeutics Holdings, Inc..
Hemab Therapeutics Holdings, Inc. investor events
Find investor webinars, events, and replay context for Hemab Therapeutics Holdings, Inc..